Jazz Pharmaceuticals (JAZZ) Equity Income (2016 - 2025)
Jazz Pharmaceuticals' quarterly Equity Income came in at -$57000.0 in Q4 2025, down 256.25% year-on-year from $36480.0 in Q4 2024, and down 21.28% quarter-over-quarter from -$47000.0 in Q3 2025.
Jazz Pharmaceuticals has reported Equity Income for 10 years, with the latest figure at -$57000.0 in Q4 2025.
- For the quarter ending Q4 2025, Equity Income fell 256.25% year-over-year to -$57000.0; the trailing twelve-month figure through Mar 2026 stood at -$190000.0 (up 76.63% YoY), and the FY2025 full-year result was -$732000.0, up 55.9% from the prior year.
- Equity Income for Q4 2025 stood at -$57000.0, down from -$47000.0 in the prior quarter.
- The five-year high for Equity Income was $4.2 million in Q1 2021, with the low at -$4.1 million in Q1 2022.
- Average Equity Income over 5 years is -$799700.0, with a median of -$480500.0 recorded in 2023.
- Year-over-year, Equity Income surged 2188.46% in 2021 and sank 616.67% in 2025.
- Tracing JAZZ's Equity Income over 5 years: stood at -$3.0 million in 2021, then jumped by 74.13% to -$773000.0 in 2022, then jumped by 40.36% to -$461000.0 in 2023, then soared by 96.53% to -$16000.0 in 2024, then sank by 256.25% to -$57000.0 in 2025.
- The last three Equity Income figures came in at -$57000.0 (Q4 2025), -$47000.0 (Q3 2025), and -$86000.0 (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 235,807.00 |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | - |
| 10 | Jazz Pharmaceuticals | 14.64 Bn | 12.79 Bn | 934.80 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -57,000.00 |
| Sep 30, 2025 | -47,000.00 |
| Jun 30, 2025 | -86,000.00 |
| Mar 31, 2025 | -500,000.00 |
| Dec 31, 2024 | -16,000.00 |
| Sep 30, 2024 | -285,000.00 |
| Jun 30, 2024 | -12,000.00 |
| Mar 31, 2024 | -1.35 Mn |
| Dec 31, 2023 | -461,000.00 |
| Sep 30, 2023 | 126,000.00 |
| Jun 30, 2023 | -1.67 Mn |
| Mar 31, 2023 | -1.01 Mn |
| Dec 31, 2022 | -773,000.00 |
| Sep 30, 2022 | -2.55 Mn |
| Jun 30, 2022 | -2.46 Mn |
| Mar 31, 2022 | -4.14 Mn |
| Dec 31, 2021 | -2.99 Mn |
| Sep 30, 2021 | -3.26 Mn |
| Jun 30, 2021 | 1.37 Mn |
| Mar 31, 2021 | 4.17 Mn |
| Dec 31, 2020 | -624,000.00 |
| Sep 30, 2020 | -623,000.00 |
| Jun 30, 2020 | -1.90 Mn |
| Mar 31, 2020 | 182,000.00 |
| Dec 31, 2019 | -1.30 Mn |
| Sep 30, 2019 | -1.03 Mn |
| Jun 30, 2019 | -868,000.00 |
| Mar 31, 2019 | -893,000.00 |
| Dec 31, 2018 | -843,000.00 |
| Sep 30, 2018 | -437,000.00 |
| Jun 30, 2018 | -586,000.00 |
| Mar 31, 2018 | -337,000.00 |
| Dec 31, 2017 | -372,000.00 |
| Sep 30, 2017 | -273,000.00 |
| Jun 30, 2017 | -203,000.00 |
| Mar 31, 2017 | -161,000.00 |
| Dec 31, 2016 | -276,000.00 |
| Sep 30, 2016 | -103,000.00 |